Metabolic changes in patients with prostate cancer with androgen deprivation therapy
Prostate cancer is the most common type of cancer among men. Androgen deprivation therapy (ADT) is the most effective treatment for this disease. The cornerstone of prostate cancer treatment is the inhibition of testosterone production, which interrupts testosterone-induced growth of the prostate tu...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2020-06-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/10343 |
| _version_ | 1826588037941821440 |
|---|---|
| author | Maxim N. Peshkov Galina P. Peshkova Igor V. Reshetov |
| author_facet | Maxim N. Peshkov Galina P. Peshkova Igor V. Reshetov |
| author_sort | Maxim N. Peshkov |
| collection | DOAJ |
| description | Prostate cancer is the most common type of cancer among men. Androgen deprivation therapy (ADT) is the most effective treatment for this disease. The cornerstone of prostate cancer treatment is the inhibition of testosterone production, which interrupts testosterone-induced growth of the prostate tumour. A sharp decrease in testosterone, however, has several undesirable effects on the metabolic profile and bone metabolism and can also lead to fatigue, loss of libido, gynecomastia and anaemia, provoke vasomotor hyperaemia and generally affect the quality of life. To increase the good (long-term) survival of patients with prostate cancer, studying the side effects associated with treatment is important, and therefore, in every clinical situation, the benefits of ADT must be compared with the side effects associated with the treatment. This article focuses on the described metabolic complications of ADT, including obesity, diabetes, lipid changes, metabolic syndrome and cardiovascular diseases. It also contains practical recommendations for managing the side effects and complications based on the available guidelines issued by the medical professional community. |
| first_indexed | 2024-03-08T15:19:59Z |
| format | Article |
| id | doaj.art-3884afa15db648edbc942fa54a507248 |
| institution | Directory Open Access Journal |
| issn | 2072-0351 2072-0378 |
| language | English |
| last_indexed | 2025-03-14T16:34:58Z |
| publishDate | 2020-06-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj.art-3884afa15db648edbc942fa54a5072482025-02-21T09:29:36ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782020-06-0123219220010.14341/DM1034310670Metabolic changes in patients with prostate cancer with androgen deprivation therapyMaxim N. Peshkov0Galina P. Peshkova1Igor V. Reshetov2Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies FMBA of RussiaRyazan State Medical UniversityI.M. Sechenov First Moscow State Medical UnivesityProstate cancer is the most common type of cancer among men. Androgen deprivation therapy (ADT) is the most effective treatment for this disease. The cornerstone of prostate cancer treatment is the inhibition of testosterone production, which interrupts testosterone-induced growth of the prostate tumour. A sharp decrease in testosterone, however, has several undesirable effects on the metabolic profile and bone metabolism and can also lead to fatigue, loss of libido, gynecomastia and anaemia, provoke vasomotor hyperaemia and generally affect the quality of life. To increase the good (long-term) survival of patients with prostate cancer, studying the side effects associated with treatment is important, and therefore, in every clinical situation, the benefits of ADT must be compared with the side effects associated with the treatment. This article focuses on the described metabolic complications of ADT, including obesity, diabetes, lipid changes, metabolic syndrome and cardiovascular diseases. It also contains practical recommendations for managing the side effects and complications based on the available guidelines issued by the medical professional community.https://www.dia-endojournals.ru/jour/article/view/10343prostate cancermetabolic syndromediabetes mellitusinsulin resistancebody vass indexobesitydyslipidemia |
| spellingShingle | Maxim N. Peshkov Galina P. Peshkova Igor V. Reshetov Metabolic changes in patients with prostate cancer with androgen deprivation therapy Сахарный диабет prostate cancer metabolic syndrome diabetes mellitus insulin resistance body vass index obesity dyslipidemia |
| title | Metabolic changes in patients with prostate cancer with androgen deprivation therapy |
| title_full | Metabolic changes in patients with prostate cancer with androgen deprivation therapy |
| title_fullStr | Metabolic changes in patients with prostate cancer with androgen deprivation therapy |
| title_full_unstemmed | Metabolic changes in patients with prostate cancer with androgen deprivation therapy |
| title_short | Metabolic changes in patients with prostate cancer with androgen deprivation therapy |
| title_sort | metabolic changes in patients with prostate cancer with androgen deprivation therapy |
| topic | prostate cancer metabolic syndrome diabetes mellitus insulin resistance body vass index obesity dyslipidemia |
| url | https://www.dia-endojournals.ru/jour/article/view/10343 |
| work_keys_str_mv | AT maximnpeshkov metabolicchangesinpatientswithprostatecancerwithandrogendeprivationtherapy AT galinappeshkova metabolicchangesinpatientswithprostatecancerwithandrogendeprivationtherapy AT igorvreshetov metabolicchangesinpatientswithprostatecancerwithandrogendeprivationtherapy |